Portal Innovations

Synaptrix specializes in developing innovative, non-opioid pain management solutions. The company focuses on creating medical devices that employ neuromodulation technology, using electrical or chemical stimulation to alleviate postoperative pain without compromising motor function or touch. This approach aims to provide healthcare professionals with effective, long-lasting alternatives to opioids, promoting rehabilitation and reducing the need for these medications.

CrossBridge Bio is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) aimed at transforming cancer treatment. The company utilizes proprietary linker technology and enzymatic conjugation methods to create stable, targeted ADC therapeutics. This approach allows for enhanced efficacy and safety profiles, offering potential improvements in cancer therapy. CrossBridge Bio's commitment to innovation in ADC therapeutics positions it as a key player in the biotechnology sector, dedicated to advancing treatment options for patients with cancer.

March Biosciences is a clinical-stage biotechnology company specializing in cell therapies for hematological cancers. It focuses on developing CAR-T cell therapies, with its lead product, MB-105, targeting CD5 in refractory T-cell lymphoma and leukemia. The company's approach involves biologically informed target selection, simplified CAR-T engineering, and a streamlined manufacturing process to ensure cell functionality and consistency.

SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.

Alnair Therapeutics is a preclinical stage company specializing in precision oncology, dedicated to developing innovative solutions for challenging malignancies. The company has pioneered a unique drug delivery technology that harnesses the distinctive characteristics of cancer metabolism to enhance the targeting and penetration of therapeutic agents directly into cancer cells. This approach aims to improve treatment outcomes for patients suffering from difficult-to-treat cancers, addressing a significant need in the oncology field.

Dimension Inx Corp., established in 2016 and based in Chicago, Illinois, specializes in designing and developing advanced biomaterials for research and commercial applications. The company focuses on creating three-dimensional (3D) printable materials and objects that mimic natural tissues, aiming to restore tissue and organ function. Dimension Inx's portfolio includes products such as Hyperelastic bone, 3D graphene, fluffy-x, and tissue papers, all designed to facilitate regenerative medicine and medical device applications. The company's unique biomaterials platform considers the intricate interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body, enabling clinicians to promote self-healing without resorting to organ transplantation.

Syntis Bio is a late-stage preclinical company focused on developing a new class of therapies. The company designs innovative formulations for oral treatments that target specific tissues, thereby enhancing bioavailability. This approach aims to enable more effective interventions for patients across a broader range of diseases.

Cardiosense is a company that focuses on developing a physiological waveform AI platform aimed at creating predictive biomarkers for disease detection and treatment. By mining raw biosignals, Cardiosense provides enhanced visibility into cardiac functions and employs advanced signal processing techniques to identify pre-symptomatic markers of cardiac disease. The company specializes in utilizing non-invasive sensors and proprietary algorithms, which allow healthcare professionals to monitor and analyze cardiac health signals effectively. This innovative approach enables the early detection of diseases, thereby facilitating improved patient care and health tracking.

ClostraBio, Inc. is a Chicago-based biotechnology company founded in 2016 that focuses on creating therapeutics to prevent allergic reactions to food. The company specializes in microbiome-modulating treatments aimed at enhancing the protective capabilities of the gut microbiome. ClostraBio's research emphasizes the role of intestinal microbiota in regulating allergic sensitization to food, aiming to develop new therapeutic solutions for food allergies and other immune system-related diseases. The company is committed to advancing the understanding of how intestinal microbes contribute to gut barrier function and exploring mechanisms of barrier protection. Through its innovative approaches, ClostraBio seeks to provide effective treatments for patients suffering from life-threatening food allergies.

Rhaeos is a pioneering company that has developed the world's first wearable shunt monitor, designed to enhance the quality of care for patients with hydrocephalus. Utilizing a novel thermal biosensor, Rhaeos addresses a critical clinical need by offering noninvasive, wireless patches that detect fluid flow in various bodily systems, including blood, lymph, and cerebrospinal fluid. This innovative technology enables timely treatment for chronic medical conditions, particularly in the field of neurosurgery. Founded through collaborative efforts at Northwestern University, Rhaeos exemplifies a multidisciplinary approach, integrating expertise from engineering, medicine, and management to advance patient care.

Grove Biopharma is a biotechnology company dedicated to addressing significant unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. It focuses on the discovery and development of a novel class of protein-like polymers, utilizing artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics. In addition to its drug development efforts, Grove Biopharma provides materials science solutions to challenges associated with peptide therapeutics, enabling researchers to access innovative drugs in areas where treatment options are limited. Through its advanced platform, the company aims to contribute meaningful advancements in biotechnology and healthcare.